|
Apr 26
|
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
|
|
Apr 25
|
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
|
|
Apr 24
|
Novartis bags paediatric FDA label expansion for Lutathera
|
|
Apr 24
|
Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript
|
|
Apr 24
|
Company News for Apr 24, 2024
|
|
Apr 24
|
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
|
|
Apr 23
|
Why Novartis Stock Topped the Market on Tuesday
|
|
Apr 23
|
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
|
|
Apr 23
|
How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
|
|
Apr 23
|
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
|
|
Apr 23
|
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock
|
|
Apr 23
|
Novartis Stock Jumps After Beating Expectations, Raising Guidance
|
|
Apr 23
|
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
|
|
Apr 23
|
Novartis raises full-year guidance on Q1 beat, drug sales
|
|
Apr 23
|
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 23
|
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
|
|
Apr 23
|
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
|
|
Apr 23
|
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
|
|
Apr 23
|
Former Bristol Myers CEO tapped as Novartis’ next board chair
|
|
Apr 23
|
Novartis raises forecasts as top drug sales beat Wall Street estimates
|